Table 3.
Prognostic utility of the MPI within mutational subgroups of NSCLC in the microarray training and validation meta-cohorts
| Gene | Status | Meta-cohort microarray training set | Meta-cohort microarray validation set | ||||
|---|---|---|---|---|---|---|---|
| n | HR (95% CI) | P* | n | HR | P* | ||
| KRAS | wt | 187 | 1.02 (1.01 to 1.04) | <.001 | 167 | 1.03 (1.02 to 1.05) | <.001 |
| mut | 33 | 1.04 (1.01 to 1.08) | .019 | 41 | 1.01 (0.99 to 1.04) | .26 | |
| EGFR | wt | 90 | 1.02 (1.01 to 1.04) | .014 | 81 | 1.03 (1.01 to 1.04) | <.001 |
| mut | 85 | 1.02 (1.00 to 1.04) | .023 | 87 | 1.02 (1.00 to 1.05) | .041 | |
| TP53 | wt | 43 | 1.04 (1.01 to 1.06) | .002 | 35 | 1.04 (1.01 to 1.07) | .004 |
| mut | 21 | 1.02 (0.99 to 1.05) | .120 | 17 | 1.03 (1.00 to 1.06) | .033 | |
| ALK fusion | yes† | 9 | - | - | 2 | - | - |
| no | 101 | 1.02 (1.00 to 1.04) | .031 | 114 | 1.03 (1.01 to 1.04) | .001 | |
* Two-sided likelihood ratio test. CI = confidence interval; HR = hazard ratio; MPI = molecular prognostic index; mut = mutant; NSCLC = non–small cell lung cancer; wt = wild-type.
† Too few samples for assessment.